Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) fell 4.5% on Friday . The stock traded as low as $23.36 and last traded at $23.37, with a volume of 10,426,314 shares trading hands. The stock had previously closed at $24.48.

Several equities analysts have recently issued reports on VRX shares. Royal Bank Of Canada reissued a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 26th. Rodman & Renshaw reissued a “buy” rating and set a $105.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 26th. Canaccord Genuity reissued a “hold” rating and set a $40.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, April 27th. Wells Fargo & Co. reissued a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Monday, April 25th. Finally, Guggenheim reissued a “buy” rating and set a $55.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, April 25th. Seven analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and an average target price of $65.05.

The company’s market capitalization is $7.83 billion. The company has a 50 day moving average price of $22.92 and a 200 day moving average price of $47.25.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by $0.10. The company earned $2.37 billion during the quarter, compared to analysts’ expectations of $2.34 billion. During the same quarter last year, the business posted $2.36 EPS. Valeant Pharmaceuticals International’s revenue was up 9.3% compared to the same quarter last year. On average, equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.58 EPS for the current year.

In other news, CEO Joseph C. Papa purchased 202,000 shares of the stock in a transaction on Friday, June 10th. The stock was bought at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the transaction, the chief executive officer now owns 2,442,199 shares in the company, valued at approximately $59,785,031.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Several institutional investors recently modified their holdings of VRX. New York State Common Retirement Fund boosted its position in shares of Valeant Pharmaceuticals International by 64.4% in the fourth quarter. New York State Common Retirement Fund now owns 276,226 shares of the specialty pharmaceutical company’s stock valued at $28,078,000 after buying an additional 108,175 shares during the period. Vanguard Group Inc. boosted its position in shares of Valeant Pharmaceuticals International by 8.0% in the fourth quarter. Vanguard Group Inc. now owns 4,440,755 shares of the specialty pharmaceutical company’s stock valued at $451,403,000 after buying an additional 330,079 shares during the period. Tredje AP fonden bought a new position in shares of Valeant Pharmaceuticals International during the fourth quarter valued at about $10,286,000. Cowen Group Inc. boosted its position in shares of Valeant Pharmaceuticals International by 144.8% in the fourth quarter. Cowen Group Inc. now owns 60,993 shares of the specialty pharmaceutical company’s stock valued at $6,200,000 after buying an additional 36,074 shares during the period. Finally, Deere & Co. boosted its position in shares of Valeant Pharmaceuticals International by 121.1% in the fourth quarter. Deere & Co. now owns 15,011 shares of the specialty pharmaceutical company’s stock valued at $1,526,000 after buying an additional 8,222 shares during the period.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.